The impact of the relationship between government and pharmaceutical enterprises on social contribution during the public health emergency: an empirical study
Qian Zhuang, Huan Wang, Qiqi Bai, Jingwen Liang

TL;DR
This study examines how the relationship between the Chinese government and pharmaceutical companies affects their social contributions during public health emergencies like the COVID-19 pandemic.
Contribution
The study introduces a new government-enterprise alignment index and shows how government guidance influences pharmaceutical companies' social contributions during crises.
Findings
Pharmaceutical companies that were more responsive to government guidance made greater social contributions during the pandemic.
Good communication between government and enterprises mediated the positive impact on social contributions.
State ownership, embedded party organizations, and location in provincial capitals positively influenced government-enterprise alignment.
Abstract
During the COVID-19 pandemic, vaccines and specific drugs are seen as indispensable solutions to ending or responding to the pandemic, and pharmaceutical enterprises are in the spotlight. The Chinese government has made active efforts to guide pharmaceutical enterprises to make appropriate social contribution during the public health emergency. This study explores how government-enterprise relationship promotes this process. Using the financial and textual data of China's listed pharmaceutical companies and policy data from the official website of the Chinese health-related government departments, this study drew the social contribution through text analysis, and established the response index of pharmaceutical companies to the government—the government-enterprise alignment index (GE_Ali) based on the formula of elasticity for reference. Then a series of regressions are used to do the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCorporate Social Responsibility Reporting · Corporate Taxation and Avoidance · Taxation and Compliance Studies
